

Abstract of the Disclosure

A disease associated with inflammation under non-ischemic conditions is treated or prevented by administering (1)  $\alpha$ -melanocyte stimulating hormone ( $\alpha$ -MSH) and/or a  $\alpha$ -MSH equivalent, and/or (2) erythropoietin (EPO) and/or an EPO equivalent, to the individual in need thereof.

09645717 112801